ArticleVeterinary and comparative oncology2021
Are B-symptoms more reliable prognostic indicators than substage in canine nodal diffuse large B-cell lymphoma.
Article in Veterinary and comparative oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 9 citations in OpenAlex.
- Survival outcomes of dogs with multicentric lymphoma treated with sequential half-body radiotherapy and L-CHOP without maintenance chemotherapy.Journal of veterinary internal medicine · 2026Article
- Predictive Value of CorrectedWorld journal of nuclear medicine · 2024Article
- Development and validation of nomogram prognostic model for predicting OS in patients with diffuse large B-cell lymphoma: a cohort study in China.Annals of hematology · 2023Article
- Review of Canine Lymphoma Treated with Chemotherapy-Outcomes and Prognostic Factors.Veterinary sciences · 2023Review
- Clinical outcome and Ki67 evaluation in dogs with nodal small cell B-cell lymphoma diagnosed by flow cytometry.Journal of veterinary internal medicine · 2022Article
- Are B-symptoms more reliable prognostic indicators than substage in canine nodal diffuse large B-cell lymphoma.Veterinary and comparative oncology · 2021Article
- Evaluation of the clinical outcome of hypercalcemia of malignancy and concurrent azotemia in dogs with lymphoma.Journal of veterinary internal medicineArticle
- A Comprehensive Landscape of B Symptoms in Mantle Cell Lymphoma Reveals Heterogeneity Associated With Different Primary Sites.Cancer control : journal of the Moffitt Cancer CenterObservational
- Comparison of CHOP-19 and CHOP-25 for treatment of peripheral nodal B-cell lymphoma in dogs: A European multicenter retrospective cohort study.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In humans B-symptoms refer to systemic symptoms of lymphoma such as fever, weight loss, and night sweats and influence the prognosis of patients. In canine lymphoma, substage B is used to describe any clinical sign observed. Aim of the retrospective study was to compare the prognostic value of substage B with B-symptoms to predict treatment response and survival in canine nodal diffuse large B-cell lymphoma. Affected dogs treated with CHOP chemotherapy between 2008 and 2019 were included. B-symptoms were defined by weight loss greater than 10% of normal weight, fever and the occurrence of unexplained resting tachypnoea substituted human night sweats. Substage B was defined as any symptoms but lymphadenopathy. Fifty-five cases were included. B-symptoms were present in 20/55 (36%) and substage B in 40/55 (74%) patients. No significant associations between B-symptoms or substage B and weight, sex, breed, WHO stage and lymphoma grade were found. Treatment response was negatively associated with both substage B (P = .02) and B-symptoms (P = .001). B-symptoms significantly decreased progression free survival (PFS) (95 vs 330 days, P = .001) and lymphoma specific survival (LSS) (160 vs 462 days, P = .001). Data showed that B-symptoms might be a more reliable prognostic indicator than substage B in canine nodal diffuse large B-cell lymphoma. Prospective studies assessing B-symptoms in a larger cohort of patients and in other common lymphoma types are warranted. The abstract was presented at the fourth meeting of the European Canine Lymphoma Network Group in Lugano, 22 June 2019 and published in the proceeding of the meeting on the page 26.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.